GC Cell Confirms Recurrence Suppression of Immuncell LC Injection in Liver Transplant Hepatocellular Carcinoma Patients

"Potential for Managing Recurrence Risk After Curative Treatment"

GC Cell announced on September 11 that it presented research results at the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO 2026), confirming the safety of Immuncell LC injection, its potential to suppress recurrence, and its ability to improve overall survival rates in patients with hepatocellular carcinoma at high risk of recurrence after liver transplantation.

This study conducted a retrospective comparative analysis of patients who had received liver transplantation despite exceeding the standard 'Milan criteria' for hepatocellular carcinoma. The analysis compared a group of patients who were administered Immuncell LC injection beginning four weeks after liver transplantation with a control group that did not receive any additional treatment.

GC Cell presented research results at the International Association of Surgeons, Gastroenterologists and Oncologists (IASGO 2026) confirming the safety, recurrence suppression, and potential improvement in overall survival of Immuncell-LC injection for hepatocellular carcinoma patients with a high risk of recurrence after liver transplantation. GC Cell

The results showed that Immuncell LC injection was generally well tolerated, and no toxicity was observed. There was no significant difference in rejection-free survival rates between the Immuncell LC group and the control group. However, the two-year recurrence-free survival (RFS) rate was higher in the Immuncell LC group at 87.5%, compared to 62.9% in the control group. Overall survival (OS) was also higher in the Immuncell LC group at 100%, compared to 81.5% in the control group.

Hong Geun, head of the Transplantation Center at Ewha Womans University Seoul Hospital, stated, "Liver transplant recipients are at heightened risk of compromised immune function and rejection due to the use of immunosuppressants, and treatment becomes even more challenging if liver cancer recurs after transplantation. This study is meaningful in that it confirmed the potential of Immuncell LC injection as a treatment option to prevent recurrence in patients with high risk of post-transplant hepatocellular carcinoma recurrence."

Moon Jongsik, Head of the Oncology Division at GC Cell, said, "We will continue to explore the potential of Immuncell LC injection as a long-term recurrence management therapy for patients with hepatocellular carcinoma who continue to face recurrence risks even after curative treatment."

This content was produced with the assistance of AI translation services.